

Greenhouse Fund Recipient



**EAGLE VISION
PHARMACEUTICAL CORP.**

Eagle Vision Pharmaceutical Corp. is a private corporation leading the industry in the discovery and development of novel diagnostic imaging (DI) agents that identify the presence, nature and extent of disease, improve treatment planning and predict and confirm the response to therapy. Covered by issued and pending patents, the company's product candidates enhance Magnetic Resonance Imaging's (MRI) powerful potential for diagnosis and management of heart disease, liver disease and cancer to replace the more limited, costly and invasive procedures currently used. DI agents are fundamental to cost-effective health care and cost containment. The ability to diagnose disease accurately and early is important for proper choice of treatment and for cure, leading to an increased quality and length of life. MRI provides superior diagnostic capabilities for many areas of the body. Thus far, the company has been awarded four National Institutes of Health SBIR grants totaling nearly \$2 million in support of its programs.



Current Exam



EVP 1000-1 Exam

The company's most advanced program involves the development of EVP 1001-1 as the first nonradioactive agent that is specific for cardiac imaging and diagnosis. EVP 1001-1 overcomes the primary factor limiting broader use of MRI for the heart, which is the lack of a cardiac-specific agent. EVP 1001-1 identifies areas of the heart receiving inadequate blood supply, indicates which areas will benefit from invasive and expensive treatment and confirms the benefit following treatment. No other test offers such diagnostic information, which may only be approximated by the combined results of several procedures. EVP 1001-1 has the potential to make a noninvasive, cost-effective "one stop shop" MRI cardiac exam a reality. The initial subsegment that EVP 1001-1 is projected to dominate is cardiac perfusion, a \$700 million product segment with double-digit growth.

Proposed Project

Eagle Vision recently completed the Phase I human study for EVP 1001-1. BioAdvance funding will be used to support critical activities needed for initiating the Phase II clinical program, which will be used to evaluate human safety and confirm dose and efficacy in the relevant patient populations. The company plans to complete the Phase II studies in 2004, and will be raising additional capital to fund the clinical program.

A second program, EVP-ABD, targets the liver and other abdominal organs. A third program promises to provide the anatomical, perfusion, metabolic and functional information desired in a single, noninvasive, high resolution study to elucidate fundamental physiology of tumors and their therapy at the cellular level, overcoming the high costs, radiation and limited resolution of Positron Emission Tomography (PET) imaging for cancer.

Management

Phillip P. Harnish, Ph.D., Chairman and Chief Executive Officer, has over 28 years of experience in pharmaceutical research and development in both academia and industry, with expertise in cardiovascular, central nervous system and renal physiology and DI. He received his Ph.D. in Pharmacology from the University of Rochester School of Medicine, has authored more than 30 publications and secured two patents.

Peter R. Seoane, Ph.D., Vice President of R&D, has primary responsibility for preclinical research and pharmaceutical and clinical development. He has 22 years of pharmaceutical experience and holds a Ph.D. in Chemistry from Lehigh University.

For more information, contact: Philip P. Harnish, Ph.D., Chairman and Chief Executive Officer, Eagle Vision Pharmaceutical Corporation, 50 West Welsh Pool Road, Exton, PA 19341, e: mail@eaglevpc.com, p: (610) 363-6928, f: (610) 363-6927, www.eaglevpc.com